______________________________________________________
GeoVax Receives Ebola Vaccine Patent
https://www.ebolaoutbreakmap.com/listings/ebola-vaccine/
GeoVax has demonstrated that a single intramuscular (IM) dose of its ebola vaccine provided 100% protection in rhesus macaques monkeys injected with a lethal dose of Ebola virus (EBOV). This is the first report that a replication-deficient MVA vector can confer full protection against a lethal EBOV challenge after a single-dose vaccination in macaques. GEO-EM01 is based on the Company’s novel Modified Vaccinia Ankara (MVA) Virus-Like Particle (VLP) platform, which generates noninfectious VLPs in the individual being vaccinated. VLPs mimic a natural infection, triggering the body to produce a robust and durable immune response with both antibodies and T cells.
In addition to its Ebola vaccine GeoVax is also developing preventive vaccines for other hemorrhagic fever viruses highly lethal to humans. In July 2021, the Company announced results of preclinical efficacy studies of its ebola vaccine in which a single dose of the vaccine protected 100% of animals challenged with a lethal dose of SUDV. This is the first report that a replication-deficient MVA vector may confer full protection against SUDV after a single dose. This work was conducted in collaboration with researchers at the University of Texas Medical Branch (UTMB). Separately, GeoVax is leading a multi-party collaboration for the development of its SUDV and Marburg virus (MARV) vaccine candidates. The collaboration, between GeoVax, researchers at UTMB and Battelle Memorial Institute, utilizes the suite of preclinical services from NIAID. Under the collaboration, GeoVax’s SUDV and MARV vaccine candidates are being tested for immunogenicity and efficacy in the benchmark nonhuman primate model. Additionally, GeoVax’s vaccine against Lassa Fever virus (LASV) is progressing in preclinical studies with funding support from the U.S. Department of Defense.
David Dodd, GeoVax President and CEO, commented, “While our corporate focus and development priorities continue to be our C------9 vaccine and cancer immunotherapy programs, developing vaccines against lethal hemorrhagic fever viruses is also of interest and under consideration as part of our longer-term focus. This patent allowance adds to our growing portfolio of wholly owned, co-owned, and in-licensed intellectual property, which now stands at over 70 granted or pending patent applications spread over 20 patent families.”
______________________________________________________
Contact Author
If you wish to contact the author of this article. Please email us at [voyagesoflight@gmail.com]. Availability of author’s contact information depends on if said article was user submitted or reposted.
______________________________________________________
Guest Posting
If you wish to write and/or publish an article on Operation Disclosure all you need to do is send your entry to [voyagesoflight@gmail.com] applying these following rules.
The subject of your email entry should be: “Entry Post | (Title of your post) | Operation Disclosure”
– Must be in text format
– Proper Grammar
– No foul language
– Your signature/name/username at the top
______________________________________________________
Newsletter
If you wish to receive the daily Operation Disclosure Newsletter, you can subscribe via the PayPal “Subscribe” button located at the bottom.
______________________________________________________
Operation Disclosure is an independent media platform dedicated to exploring global geopolitics and alternative perspectives. Our mission is to provide a central hub for diverse viewpoints on world events, including independent research into exopolitics, aerial phenomena (UAP), and the historical origins of humanity. We believe in providing a platform for information that encourages deeper inquiry into the world around us.
Disclaimer: The content on Operation Disclosure—including articles, videos, and images—is contributed by our readers or curated for informational and educational interest. Views, opinions, and claims expressed in these posts belong solely to the authors and do not necessarily reflect the official policy or position of Operation Disclosure. We do not guarantee the absolute accuracy or completeness of this content; therefore, we encourage all readers to engage with the material with a spirit of personal inquiry and discernment.
Copyright © Operation Disclosure Official
